Brief: Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant In Congenital Adrenal Hyperplasia (Cah)
22/01/2026 23:10
Jan 22 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O: CRINETICS INITIATES PHASE 2/3 PEDIATRIC TRIAL EVALUATING ATUMELNANT IN CONGENITAL ADRENAL HYPERPLASIA (CAH) Source text: ID:nGNX4YjjrM Further company coverage: CRNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crinetics Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million